Detailed narrative
INVINCIBLE-3 Study Resumption and Protocol Modifications
The Phase 3 INVINCIBLE-3 clinical trial, testing INT230-6 as monotherapy for soft tissue sarcomas, resumed new patient enrollment in a limited number of U.S. sites in April 2026 after a pause since March 2025 due to funding. During the pause, 21 enrolled patients continued treatment or follow-up. The company engaged key investigators and sarcoma thought leaders, leading to protocol modifications reviewed by the FDA. These changes include excluding patients with tumors above 15 centimeters and implementing a central reader for scan analysis to ensure consistency. Preparations are underway to restart the study in France, Germany, Italy, Poland, and Spain, with over 60 qualified sites previously contracted or in negotiations.
INVINCIBLE-4 Study Resumption and Preliminary Efficacy Data
The Phase 2 INVINCIBLE-4 study for early-stage operable triple-negative breast cancer (TNBC) resumed patient treatment in Switzerland in July 2026, following authorization by Swissmedic and the Swiss Ethics Committee of an amended protocol. A site in France also opened for accrual after authorization by the European Medicines Agency. The amended protocol for Cohort A now uses a single injection with reduced drug volume to address localized skin issues that caused a prior enrollment pause. Preliminary data from 14 patients showed 71% pathologic complete response (pCR) in Cohort A (INT230-6 + standard of care) compared to 42% in Cohort B (standard of care alone), with a trend towards reduced Grade 3 adverse events in Cohort A.
Clinical Publications and Scientific Influence
In November, the Lancet group's journal eBioMedicine published safety and efficacy data from the Phase 1/2 IT-01 study on INT230-6 monotherapy for metastatic or refractory cancers. The paper reported a disease control rate of 75% for metastatic patients and a median overall survival of nearly 12 months for 64 patients, significantly higher than typical systemic therapies. Patients receiving over 40% of their visible tumor burden had a median overall survival of 18.7 months, and nearly 20% showed an abscopal effect. The journal has an impact factor of 11 and ranks 19th out of 191 in its category, underscoring the scientific rigor and influence of the published data.
Financial Position and Capital Raising Efforts
As of June 30, 2026, Intensity Therapeutics held $9.5 million in cash and cash equivalents. The company raised $1.6 million in net proceeds during Q2 2026 from its $60 million at-the-market (ATM) facility established in March 2026. An additional $1.3 million in net proceeds has been raised through the ATM facility since June 30, 2026. Management plans to continue utilizing the ATM facility opportunistically to raise capital, aiming to scale up clinical activities. The operating cash burn for the first half of 2026 was $4.2 million, with an estimated average burn of $1 million per month for the second half of 2026.
Business Development and Partnership Strategy
Intensity Therapeutics actively pursued potential partnerships, holding over 20 meetings with strategic partners at the BIO International Convention in late June. The company noted strong interest driven by its recent clinical publications. Discussions are ongoing with multinational and regional players, with the goal of accelerating global access to the drug. While early, the company is evaluating all options for collaboration, including global rights or regional agreements, to advance its programs and reach more patients effectively.